Yiwu Yan, PhD, received his doctorate in biochemistry and molecular biology from Peking Union Medical College, Beijing, China in 2015. During his predoctoral training, Yan's research projects were mainly focused on the molecular mechanisms and therapy of acute lung injury. After obtaining his PhD, Yan joined the Yang Laboratory for his postdoctoral training. His current research interest is developing and applying leading-edge proteomics technologies to discover clinically useful protein biomarkers to distinguish aggressive from indolent prostate cancer (PCa), and to identify clinically actionable protein targets for more effective treatment of lethal PCa. Specifically, Yan's research projects include: applying various proteomics methods, such as label-free proteomics, phosphoproteomics and interactome profiling, to characterize the functions and underlying molecular mechanisms of Receptor-interacting serine/threonine-protein kinase 2 in PCa progression; developing a novel method for proteome-scale analysis of S-acylation (more commonly known as palmitoylation) site occupancy; and studying the functions of palmitoyl acyltransferases in PCa progression and characterizing their downstream palmitoyl-protein networks using leading-edge palmitoyl-proteomics methods developed by the Yang Lab. Yan is a recipient of the highly prestigious Department of Defense Prostate Cancer Research Program Early Investigator Research Award (2018–20).
Yang "Oliver" Wang, PhD, received his bachelor's degree in biotechnology from Nanjing Medical University in China. He obtained his master of science in biomedical and molecular sciences research from King's College London in the U.K., and his doctorate in chemistry from Osaka University in Japan. Wang completed his dissertation work developing a nonprobability-based protein identification method by the observation of C-terminally truncated b-type metastable ions in matrix assisted laser desorption/ionization mass spectra under the supervision of Toshifumi Takao, PhD. Wang received his postdoctoral training in cancer biology at City of Hope National Medical Center in Southern California. In March 2018, he joined the Yang Laboratory to conduct research in the field of cancer proteomics. Wang's research focuses on developing a more rapid and sensitive method to analyze protein S-acylation (more commonly known as palmitoylation) on the basis of the palmitoyl protein identification and site characterization method developed by the Yang Lab, as well as mapping the substrates of an oncogenic palmitoyl acyltransferase DHHC11 in prostate cancer cells and investigating its functions in prostate cancer progression.